Author

Jesse A. Leissa

Observed names: Jesse A Leissa, Jesse Leissa, Leissa, Jesse Alton

Observed institutions: United States Food and Drug Administration, Center for Drug Evaluation and Research, AstraZeneca (United States), University of Maryland, College Park

ORCID: 0000-0001-8831-8934

Observed ORCID: 0000-0001-8831-8934

OpenAlex ID: A5083254375

Understanding syringeability and injectability of high molecular weight PEO solution through time-dependent force-distance profiles

2022 · Xin Feng, Kai-Wei Wu, et al. · International Journal of Pharmaceutics · 22

Histatin 5 variant reduces Candida albicans biofilm viability and inhibits biofilm formation

2021 · Parisa Moghaddam-Taaheri, Jesse A. Leissa, et al. · Fungal Genetics and Biology · 16

Qualitative High-Throughput Analysis of Subvisible Particles in Biological Formulations Using Backgrounded Membrane Imaging

2022 · Markela Ibo Murphy, Maria Bruque, et al. · Journal of Pharmaceutical Sciences · 13

Beyond function: Engineering improved peptides for therapeutic applications

2019 · Sayanee Adhikari, Jesse A. Leissa, et al. · AIChE Journal · 13

Effect of Various Silicone Oil And Tungsten Levels on the Stability of a Monoclonal Antibody in Nine Commercially Available Prefilled Syringes

2023 · Markela Ibo Murphy, Jesse A. Leissa, et al. · Journal of Pharmaceutical Sciences · 9

Assessing subvisible particle risks in monoclonal antibodies: insights from quartz crystal microbalance with dissipation, machine learning, and in silico analysis

2025 · Yibo Wang, Alexis Hanford, et al. · mAbs · 2

Protein Engineering Approaches to Improve the Therapeutic Potential of Histatin-5 for Candida albicans Infections

2019 · Leissa, Jesse Alton · University Libraries (University of Maryland)

Works count: 7

Citation count: 75

H-index: 5

I10-index: 4